Locations:
Search IconSearch
May 13, 2017/Cancer

No Stoma, One, or Two? Setting Expectations for Patients with Rectourethral Fistula

Evidence shows that good communication is key

650×450 rectourethral fistula_New Header Image_17-URL-681

When patients experience rectourethral fistula (RUF) after prostate cancer treatment, communicating about potential procedures and setting clear treatment expectations are critical steps to achieve overall patient satisfaction, according to results of a study by urologists at Cleveland Clinic Glickman Urological & Kidney Institute.

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

The research was conducted by Hadley Wood, MD; Kenneth Angermeier, MD; and Amanda Chi, MD. Dr. Chi presented results of theirs research at the American Urological Association 2017 meeting in Boston.

The study encompassed a review of 103 patients with RUF whose treatments and outcomes were followed for an average of nearly three years (31 months). Eighty percent of patients ultimately underwent surgery for RUF at Cleveland Clinic, and of that group, nearly two-thirds (60 percent) ended up with no abdominal stoma. Long-term urostomy alone was required as a component of the successful management of the RUF in 17 percent of this patient group, and colostomy or ileostomy in 15 percent. A low number of patients (9 percent) were ultimately managed with two stomas.

Patient evaluation is fairly standard, however treatment options vary and may require shifting plans and flexibility, according to Dr. Angermeier, which can leave patients wondering whether they can be fully reconstructed or will require one or two stomas in the future.

Contrast study demonstrating rectourethral fistula.

Contrast study demonstrating rectourethral fistula. Contrast outlines bladder and bowel, fistula between urethra and rectum, as well as brachytherapy seeds from prostate cancer treatment.

Explain treatment; set expectations

“A thorough discussion of treatment plans and setting realistic expectations helps patients remain content with their outcomes,” Dr. Angermeier says. “We explain that repairing a rectourethral fistula requires a long and multi-step process that consists of fecal diversion, subsequent evaluation and surgical intervention, and ultimately stoma reversal.” Patient satisfaction is higher when appropriate expectations are outlined at the initial visit.

Advertisement

For complex fistulas, Dr. Angermeier usually begins treatment by diverting the fecal stream for at least four months, after which patients are evaluated with cystoscopy and proctoscopy under anesthesia to determine whether the fistula can be repaired.

After evaluation, if both the urinary tract and rectum appear amenable to repair, physicians will recommend patients undergo repair with the ultimate goal of no stoma. Alternatively, findings may reveal that patients need at least one stoma, usually because either the rectum or urinary tract do not appear healthy enough to be repaired. Much less frequently, patients are recommended for two stomas because of extensive tissue destruction.

Patients who underwent focal prostate cancer treatments, including brachytherapy, high-intensity focused ultrasound (HIFU), cryoablation, etc., had a higher frequency of requiring at least one stoma, as opposed to those who underwent external beam radiation for rectal or prostate cancer with or without surgery, the study reported.

“In the majority of patients, reconstruction of both systems is feasible, and it is rare not to be able to repair at least one system,” Dr. Angermeier notes. “Patients are evaluated about six months postoperatively to confirm healing and that bowel continuity can be restored. At any point along the way, re-evaluation may lead to a change in the initial plan.”

RUF overview

RUF represents a painful and uncomfortable condition with a varying etiologies that arise in approximately 0.5 percent of patients after treatment for prostate cancer, notably radiation and prostatectomy.

Advertisement

In this condition, a fistula opens between the rectum and urethra, resulting in a range of symptoms, including urinary tract infection, sepsis, air bubbles in urine, feces in urine, passage of urine through the rectum, and others.

Approaches to RUF highly individualized

Because of its relative rarity and the variable nature of fistulas, RUF management remains a highly individualized proposition with a paucity of consensus on optimal techniques.

Dr. Angermeier concludes, “While the rate of RUF resolution is high, we feel that patients should be carefully counseled and carefully selected for optimal surgical management.”

Former Fellow John Lacy, MD, and medical student and Research Fellow Shree Agrawal, BS, also contributed to this research.

Advertisement

Related Articles

Doctors working on MGUS screening study
March 18, 2024/Cancer/Research
Pilot Study Aims for Early Identification of Multiple Myeloma Precursor Among Black Patients

First-of-its-kind research investigates the viability of standard screening to reduce the burden of late-stage cancer diagnoses

Hematologist at Cleveland Clinic
March 14, 2024/Cancer/Blood Cancers
Advances in Mantle Cell Lymphoma Treatment (Podcast)

Global R&D efforts expanding first-line and relapse therapy options for patients

Physician with patient
March 6, 2024/Cancer/Research
Targeting Uncontrolled Erythrocytosis in Polycythemia Vera with Rusfertide

Study demonstrates ability to reduce patients’ reliance on phlebotomies to stabilize hematocrit levels

Dr. Jagadeesh at Cleveland Clinic
February 28, 2024/Cancer/Blood Cancers
Treating Patient with Systemic T-Cell Lymphoma and Graft-Versus-Host Disease

A case study on the value of access to novel therapies through clinical trials

Doctor measuring patient's waist size
February 26, 2024/Cancer/Research
Impact of Obesity on GVHD & Transplant Outcomes in Hematologic Malignancies

Findings highlight an association between obesity and an increased incidence of moderate-severe disease

Physician with patient
February 21, 2024/Cancer/Research
Strategies for Improving Clinical Trial Equity

Cleveland Clinic Cancer Institute takes multi-faceted approach to increasing clinical trial access 23456

How antibody drug conjugates work
February 13, 2024/Cancer/Research
Real-World Use of Trastuzumab Deruxtecan

Key learnings from DESTINY trials

CQD-4445459-rotz-650×450
February 7, 2024/Cancer
Advances in Bone Marrow Transplant Have Improved Outcomes in Fanconi Anemia

Overall survival in patients treated since 2008 is nearly 20% higher than in earlier patients

Ad